Paul F Robbins Selected Research

T-Cell Antigen Receptors (T-Cell Receptor)

1/2022	Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers.
1/2022	Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.
1/2021	Rapid Identification and Evaluation of Neoantigen-reactive T-Cell Receptors From Single Cells.
1/2021	Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy.
11/2019	Tumor-infiltrating human CD4+ regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity.
11/2019	Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes.
1/2019	Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer.
11/2018	T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers.
10/2017	Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
4/2016	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul F Robbins Research Topics

Disease

87	Neoplasms (Cancer) 01/2022 - 03/2002
41	Melanoma (Melanoma, Malignant) 01/2022 - 03/2002
10	Testicular Neoplasms (Testicular Cancer) 11/2020 - 04/2005
5	Colorectal Neoplasms (Colorectal Cancer) 02/2012 - 07/2003
4	Colonic Neoplasms (Colon Cancer) 01/2019 - 10/2003
3	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2018
3	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 11/2020 - 01/2014
3	Ovarian Neoplasms (Ovarian Cancer) 11/2019 - 11/2018
3	Adenocarcinoma 01/2019 - 01/2009
3	Neoplasm Metastasis (Metastasis) 11/2018 - 01/2014
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 03/2005
2	Cholangiocarcinoma 03/2017 - 05/2014
2	Sarcoma (Soft Tissue Sarcoma) 03/2015 - 03/2011
2	Stomach Neoplasms (Stomach Cancer) 01/2014 - 03/2005
1	Carcinoma (Carcinomatosis) 01/2019
1	Hematologic Neoplasms (Hematological Malignancy) 01/2019
1	Glioblastoma (Glioblastoma Multiforme) 01/2019
1	Leukemia 01/2019
1	Lung Neoplasms (Lung Cancer) 01/2018
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2018
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2017
1	Urogenital Neoplasms 11/2015
1	Carcinogenesis 07/2014
1	Synovial Sarcoma (Synovioma) 06/2012
1	Colitis 03/2011
1	Hepatocellular Carcinoma (Hepatoma) 03/2005
1	Prostatic Neoplasms (Prostate Cancer) 03/2005
1	Esophageal Neoplasms (Esophageal Cancer) 03/2005

Drug/Important Bio-Agent (IBA)

45	AntigensIBA 01/2022 - 03/2002
28	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 03/2005
16	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 07/2002
16	Peptides (Polypeptides)IBA 10/2015 - 03/2002
12	EpitopesIBA 01/2022 - 07/2002
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2002
8	Interleukin-2 (IL2)IBA 10/2021 - 05/2008
6	HLA-A*02:01 antigenIBA 01/2019 - 07/2004
6	CytokinesIBA 01/2017 - 06/2003
4	HLA-A Antigens (HLA-A)IBA 01/2022 - 02/2005
4	HLA Antigens (Human Leukocyte Antigens)IBA 11/2018 - 04/2005
4	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 11/2015 - 07/2002
3	Differentiation AntigensIBA 11/2020 - 10/2002
3	VaccinesIBA 11/2020 - 07/2002
3	LigandsIBA 01/2019 - 07/2003
3	HLA-C Antigens (HLA-C)IBA 12/2016 - 11/2012
2	Messenger RNA (mRNA)IBA 01/2022 - 11/2020
2	InterferonsIBA 01/2021 - 04/2014
2	Mutant Proteins (Protein, Mutant)IBA 01/2019 - 01/2018
2	ElementsIBA 11/2018 - 03/2009
2	InterleukinsIBA 01/2018 - 11/2008
2	HLA-DPB1 antigen (HLA DPB1)IBA 10/2017 - 01/2016
2	Immunoglobulins (Immunoglobulin)IBA 08/2017 - 05/2014
2	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 10/2015
2	Biomarkers (Surrogate Marker)IBA 05/2014 - 03/2005
2	HLA-B Antigens (HLA-B)IBA 01/2014 - 02/2005
2	Carcinoembryonic AntigenIBA 03/2011 - 01/2009
2	AutoantigensIBA 05/2007 - 09/2002
2	RNA (Ribonucleic Acid)IBA 11/2006 - 04/2005
1	Immune Checkpoint InhibitorsIBA 01/2022
1	mRNA VaccinesIBA 11/2020
1	Cysteine (L-Cysteine)FDA Link 01/2020
1	Aminobutyrates (Aminobutyric Acid)IBA 01/2020
1	epidermal growth factor receptor VIIIIBA 01/2019
1	ErbB Receptors (EGF Receptor)IBA 01/2019
1	Chimeric Antigen ReceptorsIBA 01/2019
1	HLA-DRB3 Chains (HLA DRB3)IBA 11/2018
1	Hormones (Hormone)IBA 01/2018
1	Carrier Proteins (Binding Protein)IBA 08/2017
1	HLA-DRB1 Chains (HLA DRB1)IBA 08/2017
1	Viral AntigensIBA 01/2017
1	TransposasesIBA 01/2016
1	Growth Factor ReceptorsIBA 08/2014
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 08/2014
1	Peptide TIBA 08/2014
1	KinesinsIBA 07/2014
1	DNA Polymerase I (Klenow Fragment)IBA 07/2014
1	MucinsIBA 05/2014
1	Member 9 Tumor Necrosis Factor Receptor SuperfamilyIBA 05/2014
1	Immunodominant EpitopesIBA 06/2013
1	Protein Phosphatase 1IBA 06/2013
1	Tumor Viral Antigens (Large T Antigen)IBA 02/2012
1	Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine AmidaseIBA 07/2011
1	Monophenol Monooxygenase (Tyrosinase)IBA 07/2011
1	DepsipeptidesIBA 03/2009
1	Decitabine FDA Link 03/2009
1	Histone Deacetylase InhibitorsIBA 03/2009
1	Interferon-gamma (Interferon, gamma)IBA 03/2009
1	Therapeutic UsesIBA 03/2009
1	Dacarbazine (DIC)FDA LinkGeneric 11/2008
1	Amino Acids FDA Link 05/2008
1	Indicators and Reagents (Reagents)IBA 11/2006
1	HLA-A*23 antigenIBA 05/2005
1	B-Lymphocyte Epitopes (B-Cell Epitope)IBA 03/2005
1	Recombinant ProteinsIBA 03/2005

Therapy/Procedure

42	Immunotherapy 01/2022 - 03/2002
40	Therapeutics 01/2022 - 09/2003
9	Cell- and Tissue-Based Therapy (Cell Therapy) 11/2019 - 05/2008
9	Drug Therapy (Chemotherapy) 03/2015 - 09/2003
1	Aftercare (After-Treatment) 01/2016
1	Radiotherapy 05/2011
1	Investigational Therapies (Experimental Therapy) 03/2009